Icon

KYNAMRO (nda203568)- (200MG/ML (200MG/ML))

MIPOMERSEN SODIUM KASTLE THERAPS LLC
200MG/ML (200MG/ML)
No No
2027-Jan-29 2018-Jan-29
2020-Jan-29 None
None No
KYNAMRO ® is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).
0 0 0
Total Other Developers None
Drugs with Suitability No
200MG/ML (200MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.